Scan to get started on Sahi
Rethink Trading
A new age Broking platform with in-house Sahi charts, real-time AI intelligence, and flat ₹10 per order brokerage.
4.5 ★ . 38K+ Ratings Google Play and App Store | IFTA Startup of the year 2025 | Forbes Asia Top 100 Startups to Watch 2026 | 8M+ downloads
Built for single-screen high performance acrossOptions Buying
Options Buying
Options Buying
Introducing the new & improved Sahi Scalper 2.0
Analyse & execute on a multi-chart layout. Watch the Index and Option Charts, Call & Put, Option Chain, simultaneously without moving an eye from your P&L.
Seamless Options Trading with Powerful Tools
Stay nimble and execute faster than ever before – no matter the screen size.
Trade from Charts, at Sahi Speed
Sahi’s powerful charts are built in-house & give you full control over your trades. Manage risk, optimize entries and exits, and never miss a movement – all without leaving your chart.
Real-Time market intelligence with Sahi AI
Tracks trends, identifies breakouts, highlights the hottest stocks
Analyse, Trade Option Strategies With Confidence
Create strategies that work for you. More control, better results.
Personalized Trading:
Tailor Your Space and Strategy
Personalize your homepage layout to match your trading style. Set up your workspace the way you want it, with just the tools you need.
High Performance Trading
at Incredible Value
Pay only ₹10 per executed order.
Latest news
Indian Hume Pipe Q2 Standalone Net Profit Drops To ₹22.75 Crore Vs ₹34.69 Crore YoY
Indian Hume Pipe's Q2 standalone net profit declined to ₹22.75 crore from ₹34.69 crore year-on-year, reflecting reduced quarterly net earnings.
Kingfa Reports Q2 Consolidated Net Profit Of ₹470.3 Million Vs ₹411.4 Million YoY
Kingfa Science & Technology demonstrated resilient bottom-line performance for Q2, recording consolidated net profit of ₹470.3 million compared to ₹411.4 million YoY, representing growth of approximately 14.31%.
GPT Healthcare Reports Q2 Revenue Of ₹1.36 Billion Versus ₹1.19 Billion YoY
GPT Healthcare achieved Q2 revenue of ₹136 crore, delivering an inline YoY top-line growth of ≈14.29% compared to ₹119 crore recorded in Q2 of the prior fiscal. Operational performance continues to benefit from steady bed capacity utilization across its ILS Hospitals network.
